Clinical Trial Update: Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) [Phase 3]

View source ↗

Summary

Phase 3 trial update for intravenous mepolizumab in subjects with hypereosinophilic syndromes (HES) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilia
• Hypereosinophilic Syndrome

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypereosinophilia, Hypereosinophilic Syndrome | Phase 3 | Status: COMPLETED